Successful Desensitization of an Adult with Type I Hypersensitivity to Imatinib
The Internet Journal of Asthma, Allergy and Immunology · 2005
DOI: 10.5580/1a78 ↗At a glance
Journal article in The Internet Journal of Asthma, Allergy and Immunology, 2005. Cited 1 times so far (Crossref).
Abstract (original language)
Cutaneous reactions to imatinib, an effective treatment for chronic myeloid leukemia, have been experienced by up to 30% of patients treated with 400 mg. Current protocols illustrate graded challenges that span up to 10 weeks. The following is a case in which a five-day graded challenge protocol was used for the administration of imatinib to a patient with a history of cutaneous reaction after starting therapy.
Cite
APA
(2005). Successful Desensitization of an Adult with Type I Hypersensitivity to Imatinib. The Internet Journal of Asthma, Allergy and Immunology. https://doi.org/10.5580/1a78
Vancouver
Successful Desensitization of an Adult with Type I Hypersensitivity to Imatinib. The Internet Journal of Asthma, Allergy and Immunology. 2005. doi:10.5580/1a78
BibTeX
@article{euvimed2005,
title = {Successful Desensitization of an Adult with Type I Hypersensitivity to Imatinib},
journal = {The Internet Journal of Asthma, Allergy and Immunology},
year = {2005},
doi = {10.5580/1a78}
}
EUVIMED